NIR 2001

Verleihung des Nils-Ilja-Richter-Preises 2001

Neue Forschungsergebnisse zu Multipler Sklerose und Guillain-Barré-Syndrom.

Am 8. Juni 2001 wurde der mit 25.000 DM dotierte Nils-Ilja-Richter-Preis zum zweiten Mal vergeben.

Herr Prof. Dr. Reinhardt Rüdel (li)
im Gespräch mit dem Preisstifter, Herrn K.M. Richter (re).

Die Auszeichnung erhielten Prof. Reinhardt Rüdel und seine Arbeitsgruppe, Universität Ulm, für Fortschritte bei der Behandlung der Multiplen Sklerose und dem Guillain-Barré-Syndrom. Sie entdeckten ein Oligopeptid, das schädigend auf die Nervenerregung wirkt. Durch die Filtration des Liquors lässt sich dieses Peptid entfernen und die Symptome der Patienten verbessern. Die Preisverleihung fand im Rahmen des „2nd Interdisciplinary Symposium on the Treatment of Autoimmune Disorders“ der Deutschen Gesellschaft für Autoimmun-Erkrankungen e.V. statt.

Zusammenfassungen der Arbeiten (Abstracts NIR 2001)

Titel

CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial.

Autoren

Wollinsky K.H.; Hülser P.J.; Brinkmeier H.; Aulkemeyer P.; Bössenecker W.; Huber-Hartmann K.H.; Rohrbach P.; Schreiber H.; Weber F.; Kron M.; Büchele G.; Mehrkens H.H.; Ludolph A.C.; Rüdel R.

Quelle

Neurology; VOL: 57 (5); p. 774-80 /20010911/

Zusammenfassung

To compare CSF filtration (CSFF) and plasma exchange (PE) in the treatment of patients with Guillain-Barré syndrome (GBS). METHODS: In a prospective controlled clinical trial, 37 patients with acute GBS were randomized to receive either CSFF or PE. Inclusion criteria were fulfillment of National Institute of Neurological and Communicative Disorders and Stroke criteria and disability to walk >5 m unassisted. RESULTS: With similar baseline features in both groups (initial disability grades on the six-point grading scale of the GBS Study Group) the primary outcome variable (improvement within 28 days after randomization) was almost identical (test for equivalence p = 0.0014), the mean grade values being 0.82 in the CSFF group and 0.80 in the PE group. After 56 days, 56% (9 of 16 patients) of the CSFF group and 37% (7 of 19 patients) of the PE group had reached grade 2 (i.e., ability of unassisted walking >5 m). After 6 months, the probability to reach grade 2 was about 80% in both groups. In the CSFF group, transient pleocytosis occurred without apparent clinical complications. Clinically relevant complications were higher in the PE-treated group. CONCLUSIONS: Although the number of patients was small, the authors found that the treatment of GBS with CSFF is at least as effective as with PE. CSFF might work by removing from the CSF inflammatory mediators, autoantibodies, or other factors.

Abstract PubMed/Medline:

auf der Website: www.ncbi.nlm.nih.gov

Titel

An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system.

Autoren

Brinkmeier H.; Aulkemeyer P.; Wollinsky K.H.; Rüdel R.

Quelle

Nature medicine; VOL: 6 (7); p. 808-11 /200007/

Zusammenfassung

Reversible blockade of sodium channels by endogenous substances has been claimed to account for the fast exacerbations and relapses commonly seen in demyelinating autoimmune diseases. Evidence has been provided that in the cerebrospinal fluid of patients with multiple sclerosis or Guillain-Barré syndrome, a sodium-channel-blocking factor exists that has properties of local anesthetic agents. This factor could contribute to the
nerve conduction block and paresis seen in these disorders. We describe here a previously unknown endogenous substance in human cerebrospinal fluid with distinct channel-blocking properties even at very low (0.00001 M) concentrations. The pentapeptide with the sequence Gln-Tyr-Asn-Ala-Asp exerted its blocking action by shifting the steady-state inactivation curve of the sodium channels to more-negative potentials, as most local anesthetics do. In the cerebrospinal fluid of healthy individuals, its concentration was about 3 microM, whereas in patients with multiple sclerosis and Guillain-Barré syndrome, it increased 300-1,400%. At these concentrations, the peptide's blocking efficacy was higher than that of 50 microM lidocaine. At a concentration of 10 microM, lidocaine is able to 'unmask' subclinical lesions in multiple sclerosis; thus, the endogenous pentapeptide may well contribute to the fast changes of symptoms. Furthermore, it may become valuable as a marker of disease activity.

Abstract PubMed/Medline:

auf der Website: www.ncbi.nlm.nih.gov

Korrespondenz:

  • Prof. Dr. rer. nat.
    Reinhardt Rüdel
    Leiter der Abteilung Allgemeine Physiologie
    Albert-Einstein-Allee 11, M25
    89081 Ulm
    Tel.: 0731 - 50 - 23231
    Fax: 0731 - 50 - 23242
    e-mail: Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!